Tags · Access
compounding
Pharmacy preparation of a formulation not commercially available.
Related in this group: insurance · prior authorisation · appeals · formulary · cost per milligram · shortage · NHS · EMA · FDA · MHRA · personal import · telehealth
54 topics · page 1 of 2
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why the cheapest option is often not the cheapest
Why the cheapest option is often not the cheapest I have a specific reason for asking rather than idle curiosity, and the context is below. Cheapest option: setting out the arithmetic in full, because I have…
|
+19 | 23 | 1.2k | 12h |
|
What a regulator's shortage notice actually authorises
What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. Asking what a regulator's document actually says, since the…
|
+8 | 12 | 15k | 17h |
|
How shortages have affected compounding permissions — does this still hold?
How shortages have affected compounding permissions — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Asking about shortages directly, because I…
|
+27 | 31 | 21k | 17h |
|
Coming back to: Telehealth prescribing models in the US
Posting this under the heading it deserves: Telehealth prescribing models in the US Everything below is what sits behind that. Telehealth prescribing models — I have the observation and I do not trust my…
|
+26 | 30 | 17k | 17h |
|
[2026 update] Comparing prices across jurisdictions without misleading yourself
On the subject in the title: Comparing prices across jurisdictions without misleading yourself Working notes rather than a conclusion. Comparing prices across jurisdictions keeps being re-asked here and I…
|
2 | 809 | 23h | |
|
Tracking a shortage from primary sources rather than rumour — the long version
On the subject in the title: Tracking a shortage from primary sources rather than rumour — the long version Working notes rather than a conclusion. Tracking a shortage keeps being re-asked here and I think…
|
2 | 60 | 1d | |
|
About the Shortages category
Supply interruptions, official shortage notices, and managing an unplanned gap. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and…
|
+3 | 7 | 9.9k | 1d |
|
How shortages have affected compounding permissions
How shortages have affected compounding permissions I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to know what people here actually do about shortages,…
|
+61 | 71 | 3.6k | 2d |
|
Substitution between formats during a shortage — what changed since
Substitution between formats during a shortage — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Substitution between formats…
|
+17 | 21 | 2.7k | 9d |
|
Manufacturer assistance programmes and their eligibility rules
On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. I have spent a fortnight trying to pin manufacturer assistance programmes…
|
+37 | 42 | 32k | 11d |
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…
|
+87 | 94 | 1.1k | 21d |
|
Official shortage notices and what they authorise
Posting this under the heading it deserves: Official shortage notices and what they authorise Everything below is what sits behind that. Trying to work out what would count as evidence on official shortage…
|
+106 | 119 | 18k | 1mo |
|
Comparing prices across jurisdictions without misleading yourself
Comparing prices across jurisdictions without misleading yourself — setting out what I have, and where I think it stops being reliable. Working notes on comparing prices across jurisdictions rather than a…
|
+78 | 83 | 33k | 1mo |
|
Labelling requirements for research chemicals — the long version
Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. A narrow question about Labelling requirements for…
|
2 | 1.8k | 2mo | |
|
Managing an unplanned gap in supply
Managing an unplanned gap in supply — setting out what I have, and where I think it stops being reliable. A narrow question about managing an unplanned gap, deliberately narrow, because the broad version has…
|
+105 | 110 | 5.1k | 3mo |
|
Price changes over 2025 and 2026, tabulated and dated — does this still hold?
Price changes over 2025 and 2026, tabulated and dated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated,…
|
+147 | 156 | 18k | 3mo |
|
Why a compound being unapproved is not the same as being illegal to possess
Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Collecting what is known about compound…
|
+72 | 78 | 23k | 3mo |
|
List price versus negotiated price versus what you pay
On the subject in the title: List price versus negotiated price versus what you pay Working notes rather than a conclusion. List price versus negotiated price — I have the observation and I do not trust my…
|
+99 | 115 | 11k | 3mo |
|
About the Regulatory category
Research-use-only status, compounding rules, import restrictions, and the primary documents behind them. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 49k | 4mo | |
|
Cost per delivered dose, which is the number that matters
Cost per delivered dose, which is the number that matters — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this category…
|
+54 | 59 | 30k | 4mo |
|
Reading a regulatory notice rather than an article about it
Posting this under the heading it deserves: Reading a regulatory notice rather than an article about it Everything below is what sits behind that. Posting a small dataset on reading a regulatory notice. It is…
|
2 | 2.9k | 5mo | |
|
Research-use-only labelling: what it means and what it does not
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. A labelling question, and I would like the answer to be…
|
+100 | 110 | 37k | 5mo |
|
Coverage in the US: a map of the usual obstacles
Coverage in the US: a map of the usual obstacles — setting out what I have, and where I think it stops being reliable. Trying to establish the boundary conditions on coverage. The general claim is fine; I…
|
+46 | 50 | 7.9k | 5mo |
|
Prescription requirements and telehealth models
Prescription requirements and telehealth models Writing it up because I had to work it out twice and would rather nobody else did. Proposing that prescription requirements and telehealth models deserves a…
|
+91 | 97 | 5.4k | 7mo |
|
What a regulator's shortage notice actually authorises — what changed since
The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. Asking what a regulator's document…
|
+22 | 26 | 53k | 7mo |
|
Substitution between formats during a shortage
On the subject in the title: Substitution between formats during a shortage Working notes rather than a conclusion. The question about substitution between formats that I actually want answered is the second…
|
+114 | 123 | 47k | 7mo |
|
Pharmaceutical compounding rules, summarised from primary sources — a second dataset
Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. Asking what a regulator's document…
|
+50 | 56 | 780 | 8mo |
|
Managing an unplanned gap in supply — what changed since
On the subject in the title: Managing an unplanned gap in supply — what changed since Working notes rather than a conclusion. What changes if the standard account of Managing an unplanned gap is wrong? I ask…
|
+114 | 124 | 54k | 8mo |
|
Second pass at: Coverage in the US: a map of the usual obstacles
On the subject in the title: Second pass at: Coverage in the US: a map of the usual obstacles Working notes rather than a conclusion. Two things I would like separated before anyone answers on Coverage,…
|
4 | 62k | 9mo | |
|
About the North America category
US and Canadian regulation, compounding, and coverage. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope…
|
+3 | 7 | 43k | 9mo |